Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Nivolumab + Ipilimumab in Advanced Solid Tumors
NCT04850755Phase 1Completed
- Sponsor
- National University Hospital
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of selinexor in solid tumor, sponsored by National University Hospital. Primary endpoints: Safety and Tolerability, Maximum Tolerated Dose and 6 more. Started Mar 2021; status: completed.
02
Drugs
selinexor
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04850755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04850755.